Ovarian Cancer — Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Citation(s)
Aapro MS, Pujade-Lauriane E, et al EORTC Clinical Screening Group: Phase II study of Taxotere in ovarian cancer. Annals of Oncology 5(5):202, abstract 508, 1994.
Climent MA, Tabernero J, Albanell J, et al Preliminary results of a phase II randomized trial of docetaxel (taxotere) as a single agent chemotherapy (CT) administered weekly or 3-weekly in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol.2002;21:52a. Abstract 205.
Gervais R, Ducoloné AMD, Breton J-L, et al Multicenter, randomised, phase II trial of docetaxel (Taxotere) 75 mg/m2 q3w versus 40 mg/m2 weekly in patients with pretreated non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:310a. Abstract 1238.
Kuzur ME, Jones S, Willcutt N, et al The Sarah Cannon Cancer Center/Tennessee Oncology, Nashville, TN; Glaxo Smith Kline, Philadelphia, PA: A phase I trial of weekly topotecan and docetaxel. Proc Am Soc Clin Onc 2003;22:Abst.
Kuzur, ME, Jones S, Willcutt N, et al. A phase I trial of weekly topotecan and docetaxel. Proc Am Soc Clin Oncol. 2003;22: Abstract 2840.
Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001 Apr 1;19(7):1901-5.
McKay C III, Hainsworth J, Burris H III, et al Weekly docetaxel/gemcitabine in the treatment of elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol. 2001;20:260b. Abstract 2793.
Schütte W, Nagel S, Lautenschläger C, et al Randomized phase III study of weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:308a. Abstract 1228.
Stemmler J, Mair W, Stauch M, et al Weekly docetaxel with or without corticosteroid premedication as first or second-line treatment in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2002;21:58a. Abstract 231.
Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994 Sep;12(9):1748-53.
Vasey PA et al. Proc Am Soc Clin Onc 2001;20:Abst.1370.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
